Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
9.51
+0.22 (2.37%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Upstream Bio Revenue
In the year 2025, Upstream Bio had annual revenue of $2.85M with 20.42% growth. Upstream Bio had revenue of $668.00K in the quarter ending December 31, 2025, with 8.97% growth.
Revenue (ttm)
$2.85M
Revenue Growth
+20.42%
P/S Ratio
181.34
Revenue / Employee
$38,053
Employees
75
Market Cap
517.53M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.85M | 484.00K | 20.42% |
| Dec 31, 2024 | 2.37M | -10.00K | -0.42% |
| Dec 31, 2023 | 2.38M | 1.17M | 96.37% |
| Dec 31, 2022 | 1.21M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionUPB News
- 11 days ago - Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference - GlobeNewsWire
- 4 weeks ago - Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data - Benzinga
- 4 weeks ago - Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Upstream Bio Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Upstream Bio Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting - GlobeNewsWire
- 2 months ago - Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 - GlobeNewsWire
- 2 months ago - Upstream Bio to Participate in Upcoming March Investor Conferences - GlobeNewsWire